Skip to main content
. 2009 Apr 1;4(4):e5078. doi: 10.1371/journal.pone.0005078

Figure 4. LY411,575 decreases liver P. berghei infection in vivo and increases CM survival.

Figure 4

(A) Dose-dependent effect of LY411,575 on liver parasite load, measured by qRT-PCR. Control mice were treated with an equivalent amount of DMSO and infection was measured on livers collected 40 h after injection of 20000 P. berghei ANKA sporozoites (n = 12 for each group). **: p<0.01, ***: p<0.001. (B) Effect of i.p. injection of 10 mg/kg body weight LY411,575 on blood parasitemia of mice infected with 1000 P. berghei ANKA sporozoites. Control mice were treated with an equivalent amount of DMSO and mice were monitored daily for parasite levels in the blood and disease symptoms. (n = 13 for each group). Parasitemias on each assessed day are significantly different between the two experimental groups (p<0.001). (C) Survival curves of mice treated by i.p. injection of 10 mg/kg body weight LY411,575 and solvent-treated, control mice, infected with 1000 P. berghei ANKA sporozoites. The shaded area represents the time-window for death with CM symptoms. The two survival curves are significantly different (p<0.01). (D) Effect of i.p. injection of 10 mg/kg body weight LY411,575 on blood parasitemia of C57BL/6 mice infected with 50000 iRBC. Control mice were treated with an equivalent amount of DMSO and mice (n = 15 for each group) were monitored daily for parasite levels in the blood and disease symptoms. Parasitemias were not found to be significantly different: p = 0,5375 (day 4); p = 0,0345 (day 5); p = 0,03065 (day 6); p = 0,1446 (day 7). (E) Survival curves of mice treated by i.p. injection of 10 mg/kg body weight LY411,575 and solvent-treated, control mice, infected with 50000 iRBC sporozoites. The shaded area represents the time-window for death with CM symptoms. The two survival curves are not significantly different (p = 0.4474).